Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667416 · ClinicalTrials.gov registry record · Phase 2
Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities
A Phase 2 study of Chronic Ulcer of Lower Extremity, sponsored by Amnio Technology.
- Active
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 7
- Study locations
NCT04667416: Active Phase 2 study of Chronic Ulcer of Lower Extremity, sponsored by Amnio Technology.
NCT04667416 is a Phase 2 study of Chronic Ulcer of Lower Extremity that is active but no longer recruiting, run by Amnio Technology. The registered enrollment target is 82 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667416, a Phase 2 study of Chronic Ulcer of Lower Extremity, is active but no longer recruiting, sponsored by Amnio Technology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow for the treatment of chronic ulcers of the lower legs and feet.
Conditions Studied
Interventions
- BIOLOGICAL PalinGen Flow Amniotic Tissue Allograft
Study Locations (7)
California
- Center for Clinical Research - Carmichael
- Center for Clinical Research - Castro Valley
- Limb Preservation Platform - Fresno
- Center for Clinical Research - San Francisco
- ILD Research Center - Vista
Texas
- Acclaim Bone & Joint Institute and Plastic Surgery - Fort Worth
- Futuro Clinical Trials - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
What the registry record for NCT04667416 still lists
NCT04667416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Chronic Ulcer of Lower Extremity appearing as the primary indexed condition, and to 1 intervention - of which PalinGen Flow Amniotic Tissue Allograft is the first listed.
NCT04667416 lists 7 locations in 2 states (California, Texas).
Frequently Asked Questions
What is clinical trial NCT04667416 about?
NCT04667416 is a clinical study titled "Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities". The purpose of this study is to assess the safety and preliminary efficacy of PalinGen® Flow for the treatment of chronic ulcers of the lower legs and feet.
What is the current status of trial NCT04667416?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2021-01-19. Estimated completion is 2025-01-31.
What conditions does trial NCT04667416 study?
This clinical trial studies the following conditions: Chronic Ulcer of Lower Extremity.
What interventions are being tested in trial NCT04667416?
The interventions under investigation include: PalinGen Flow Amniotic Tissue Allograft (BIOLOGICAL).
Who is sponsoring clinical trial NCT04667416?
This trial is sponsored by Amnio Technology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04667416 being conducted?
This trial has 7 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Ulcer of Lower Extremity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04667416's enrollment target sits among peer trials
82 830th of 2000 higher than 1,167 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI